Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | TP53 | P04637 | 5/20 | 0.49 |
| ▸ | FLT3 | P36888 | 3/20 | 0.49 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31338712 | 0.85 | FLT3 (0.52) | MAPTTP53FLT3THRBLMNA | |
| SCHEMBL31338701 | 0.84 | MAPT (0.45) | MAPTTP53THRBLMNARXFP1 | |
| SCHEMBL31338694 | 0.82 | FLT3 (0.49) | MAPTTP53FLT3THRBLMNA | |
| SCHEMBL73960 | 0.78 | FLT3 (0.82) | FLT3 | |
| SCHEMBL31338679 | 0.78 | LMNA (0.53) | MAPTTP53THRBLMNARXFP1 | |
| SCHEMBL31338713 | 0.76 | FLT3 (0.46) | MAPTTP53FLT3THRBLMNA | |
| SCHEMBL31338693 | 0.74 | LMNA (0.47) | MAPTTP53THRBLMNARXFP1 | |
| SCHEMBL804976 | 0.73 | LMNA (0.48) | MAPTTP53FLT3THRBLMNA | |
| SCHEMBL31338709 | 0.72 | FLT3 (0.52) | MAPTTP53FLT3THRBLMNA | |
| SCHEMBL31338688 | 0.72 | APP (0.44) | MAPTTP53THRBLMNARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741401-A1 | BENZOTHIAZOIMIDAZOLYL COMPOUND AND USE THEREOF | ER Stress Research Institute, Inc. (JP) | 2026-05-13 | — | — | EP | disclosed |
| WO-2025009553-A1 | BENZOTHIAZOIMIDAZOLYL COMPOUND AND USE THEREOF | 小胞体ストレス研究所株式会社 | 2025-01-09 | — | — | WO | disclosed |